Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Dis Markers. 2022 Oct 13;2022:3306189. doi: 10.1155/2022/3306189. eCollection 2022.
Lung cancer is one of the major causes of cancer-related mortality worldwide. DNA repair and damage response contribute to genomic instability that accompanies tumor progression. In this study, we focus on evaluating association between DNA repair polymorphisms of EXO1, RPA1, and prognosis in lung cancer patients whom received platinum-based chemotherapy.
593 lung cancer patients were recruited in this study. We performed genotyping of 19 single nucleotide polymorphisms (SNPs) by Sequenom MassARRAY. Cox regression analysis was used to assess overall survival (OS) and progression-free survival (PFS) among SNP genotypes.
Significant differences in PFS and OS were observed in RPA1 rs5030740, EXO1 rs1776148, and rs1047840. Results showed that patients with CC genotype in rs5030740 (recessive model: = 0.034) had a better PFS. Patients with AA or/and AG genotypes in rs1776148 (additive model: = 0.004; dominant model: = 0.048) and AA genotype in rs1047840 (recessive model: = 0.023) had longer OS. We also demonstrated differences in subgroup analysis between rs5030740, rs1776148, rs1047840, and prognosis.
Our results indicated that EXO1 rs1776148, rs1047840, and RPA1 rs5030740 were significantly associated with prognosis of lung cancer. Rs1776148, rs1047840, and rs5030740 may act as prognosis markers in lung cancer patients with platinum-based chemotherapy.
肺癌是全球癌症相关死亡的主要原因之一。DNA 修复和损伤反应导致肿瘤进展过程中基因组不稳定。在这项研究中，我们专注于评估接受铂类化疗的肺癌患者中 EXO1、RPA1 的 DNA 修复多态性与预后之间的关系。
本研究纳入了 593 例肺癌患者。我们通过 Sequenom MassARRAY 对 19 个单核苷酸多态性（SNP）进行基因分型。Cox 回归分析用于评估 SNP 基因型的总生存期（OS）和无进展生存期（PFS）。
在 RPA1 rs5030740、EXO1 rs1776148 和 rs1047840 中观察到 PFS 和 OS 有显著差异。结果表明，rs5030740 中 CC 基因型的患者（隐性模型： = 0.034）具有更好的 PFS。rs1776148 中 AA 或/和 AG 基因型（加性模型： = 0.004；显性模型： = 0.048）和 rs1047840 中 AA 基因型（隐性模型： = 0.023）的患者 OS 更长。我们还在 rs5030740、rs1776148、rs1047840 与预后的亚组分析中证明了差异。
我们的结果表明，EXO1 rs1776148、rs1047840 和 RPA1 rs5030740 与肺癌的预后显著相关。rs1776148、rs1047840 和 rs5030740 可能成为接受铂类化疗的肺癌患者的预后标志物。
